These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
226 related items for PubMed ID: 9735103
1. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme. Lin S, Thomas M, Shlaes DM, Rudin SD, Knox JR, Anderson V, Bonomo RA. Biochem J; 1998 Jul 15; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103 [Abstract] [Full Text] [Related]
2. OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors. Lin S, Thomas M, Mark S, Anderson V, Bonomo RA. Biochim Biophys Acta; 1999 Jun 15; 1432(1):125-36. PubMed ID: 10366735 [Abstract] [Full Text] [Related]
3. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244. Thomson JM, Distler AM, Bonomo RA. Biochemistry; 2007 Oct 09; 46(40):11361-8. PubMed ID: 17848099 [Abstract] [Full Text] [Related]
4. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases. Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS. J Antimicrob Chemother; 1999 Jan 09; 43(1):23-9. PubMed ID: 10381097 [Abstract] [Full Text] [Related]
5. Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations. Bonomo RA, Knox JR, Rudin SD, Shlaes DM. Antimicrob Agents Chemother; 1997 Sep 09; 41(9):1940-3. PubMed ID: 9303389 [Abstract] [Full Text] [Related]
6. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. Antimicrob Agents Chemother; 2010 Feb 09; 54(2):890-7. PubMed ID: 20008772 [Abstract] [Full Text] [Related]
7. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA. J Biol Chem; 2003 Dec 26; 278(52):52724-9. PubMed ID: 14534312 [Abstract] [Full Text] [Related]
8. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. Bonomo RA, Rudin SA, Shlaes DM. FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111 [Abstract] [Full Text] [Related]
9. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors. Therrien C, Kotra LP, Sanschagrin F, Mobashery S, Levesque RC. FEBS Lett; 2000 Mar 31; 470(3):285-92. PubMed ID: 10745083 [Abstract] [Full Text] [Related]
10. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. Madec S, Blin C, Krishnamoorthy R, Picard B, Chaibi el B, Fouchereau-Péron M, Labia R. FEMS Microbiol Lett; 2002 May 21; 211(1):13-6. PubMed ID: 12052544 [Abstract] [Full Text] [Related]
11. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence. Kalp M, Totir MA, Buynak JD, Carey PR. J Am Chem Soc; 2009 Feb 18; 131(6):2338-47. PubMed ID: 19161282 [Abstract] [Full Text] [Related]
12. Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase. Bonomo RA, Dawes CG, Knox JR, Shlaes DM. Biochim Biophys Acta; 1995 Feb 22; 1247(1):113-20. PubMed ID: 7873579 [Abstract] [Full Text] [Related]
13. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Swarén P, Golemi D, Cabantous S, Bulychev A, Maveyraud L, Mobashery S, Samama JP. Biochemistry; 1999 Jul 27; 38(30):9570-6. PubMed ID: 10423234 [Abstract] [Full Text] [Related]
14. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase. Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F. J Biol Chem; 2005 Oct 14; 280(41):34900-7. PubMed ID: 16055923 [Abstract] [Full Text] [Related]
15. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA. Antimicrob Agents Chemother; 2010 Jul 14; 54(7):2867-77. PubMed ID: 20421396 [Abstract] [Full Text] [Related]
16. beta-Lactamase mutations far from the active site influence inhibitor binding. Bonomo RA, Dawes CG, Knox JR, Shlaes DM. Biochim Biophys Acta; 1995 Feb 22; 1247(1):121-5. PubMed ID: 7873581 [Abstract] [Full Text] [Related]
17. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Blazquez J, Baquero MR, Canton R, Alos I, Baquero F. Antimicrob Agents Chemother; 1993 Oct 22; 37(10):2059-63. PubMed ID: 8257123 [Abstract] [Full Text] [Related]
18. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases. Sabbagh Y, Thériault E, Sanschagrin F, Voyer N, Palzkill T, Levesque RC. Antimicrob Agents Chemother; 1998 Sep 22; 42(9):2319-25. PubMed ID: 9736556 [Abstract] [Full Text] [Related]
19. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems. Bethel CR, Taracila M, Shyr T, Thomson JM, Distler AM, Hujer KM, Hujer AM, Endimiani A, Papp-Wallace K, Bonnet R, Bonomo RA. Antimicrob Agents Chemother; 2011 Jul 22; 55(7):3465-75. PubMed ID: 21555770 [Abstract] [Full Text] [Related]